Clinical Pharmacokinetics

, Volume 44, Issue 4, pp 349–366

Role of Cytochrome P450 Activity in the Fate of Anticancer Agents and in Drug Resistance

Focus on Tamoxifen, Paclitaxel and Imatinib Metabolism
Review Article

Abstract

Although activity of cytochrome P450 isoenzymes (CYPs) plays a major role in the fate of anticancer agents in patients, there are relatively few clinical studies that evaluate drug metabolism with therapeutic outcome. Nevertheless, many clinical reports in various non-oncology fields have shown the dramatic importance of CYP activity in therapeutic efficacy, safety and interindividual variability of drug pharmacokinetics. Moreover, variability of drug metabolism in the liver as well as in cancer cells must also be considered as a potential factor mediating cancer resistance.

This review underlines the role of drug metabolism mediated by CYPs in pharmacokinetic variability, drug resistance and safety. As examples, biotransformation pathways of tamoxifen, paclitaxel and imatinib are reviewed.

This review emphasises the key role of therapeutic drug monitoring as a complementary tool of investigation to in vitro data. For instance, pharmacokinetic data of anticancer agents have not often been published within subpopulations of patients who show ultra-rapid, extensive or poor metabolism (e.g. due to CYP2D6 and CYP2C19 genotypes).

Besides kinetic variability in the systemic circulation, induction of CYP activity may participate in creating drug resistance by speeding up the cancer agent degradation specifically in the target cells. For one cancer agent, various mechanisms of resistance are usually identified within different cell clones. This review also tries to emphasise that drug resistance mediated by CYP activity in cancer cells should be taken into consideration to a greater degree.

The unequivocal identification of the metabolising enzymes involved in clinical conditions will eventually allow improvement and individualisation of anticancer agent therapy, i.e. drug dosage and selection. In addition, a more complete understanding of the metabolism of anticancer agents will assist in the prediction of drug-drug interactions, as anticancer agent combinations are becoming more prevalent.

References

  1. 1.
    Kivisto KT, Kroemer HK, Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 1995; 40: 523–30PubMedCrossRefGoogle Scholar
  2. 2.
    McLeod HL. Clinically relevant drug-drug interactions in oncology. Br J Clin Pharmacol 1998; 45: 539–44PubMedCrossRefGoogle Scholar
  3. 3.
    Beijnen JH, Schellens JH. Drug interactions in oncology. Lancet Oncol 2004; 5(8): 489–96PubMedCrossRefGoogle Scholar
  4. 4.
    Hon YY, Evans WE. Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach. Clin Chem 1998; 44: 388–400PubMedGoogle Scholar
  5. 5.
    Innocenti F, Iyer L, Ratain MJ. Pharmacogenetics: a tool for individualizing antineoplastic therapy. Clin Pharmacokinet 2000; 39: 315–25PubMedCrossRefGoogle Scholar
  6. 6.
    Ingelman-Sundberg M, Daly AK, Oscarson M, et al. Human cytochrome P450 (CYP) genes: recommendations for the nomenclature of alleles. Pharmacogenetics 2000; 10: 91–3PubMedCrossRefGoogle Scholar
  7. 7.
    Ingelman-Sundberg M, Oscarson M, Daly AK, et al. Human cytochrome P-450 (CYP) genes: a web page for the nomenclature of alleles. Cancer Epidemiol Biomarkers Prev 2001 Dec; 10(12): 1307–8PubMedGoogle Scholar
  8. 8.
    Iyer L, Ratain MJ. Pharmacogenetics and cancer chemotherapy. Eur J Cancer 1998; 34: 1493–9PubMedCrossRefGoogle Scholar
  9. 9.
    MacLeod SL, Nowell S, Massengill J, et al. Cancer therapy and polymorphisms of cytochromes P450. Clin Chem Lab Med 2000; 38: 883–7PubMedCrossRefGoogle Scholar
  10. 10.
    Kall MA, Vang O, Clausen J. Effects of dietary broccoli on human drug metabolising activity. Cancer Letters 1997; 114: 169–70PubMedCrossRefGoogle Scholar
  11. 11.
    Krishna DR, Klotz U. Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 1994; 26: 144–60PubMedCrossRefGoogle Scholar
  12. 12.
    Yu LJ, Matias J, Scudiero DA, et al. P450 enzyme expression patterns in the NCI human tumor cell line panel. Drug Metab Dispos 2001; 29: 304–12PubMedGoogle Scholar
  13. 13.
    Doherty MM, Michael M. Tumoral drug metabolism: perspectives and therapeutic implications. Curr Drug Metab 2003; 4: 131–49PubMedCrossRefGoogle Scholar
  14. 14.
    Huang L, Wring SA, Woolley JL, et al. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab Dispos 2001; 29: 754–60PubMedGoogle Scholar
  15. 15.
    Schrenk D, Gant TW, Michalke A, et al. Metabolic activation of 2-acetylaminofluorene is required for induction of multidrug resistance gene expression in rat liver cells. Carcinogenesis 1994; 15: 2541–6PubMedCrossRefGoogle Scholar
  16. 16.
    Burt RK, Thorgeirsson SS. Coinduction of MDR-1 multidrugresistance and cytochrome P-450 genes in rat liver by xenobiotics. J Natl Cancer Inst 1988; 80: 1383–6PubMedCrossRefGoogle Scholar
  17. 17.
    Kim RB, Wandel C, Leake B, et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 1999; 16: 408–14PubMedCrossRefGoogle Scholar
  18. 18.
    Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995; 13: 129–34PubMedCrossRefGoogle Scholar
  19. 19.
    Cummings J, Zelcer N, Allen JD, et al. Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins. Biochem Pharmacol 2004; 67(1): 31–9PubMedCrossRefGoogle Scholar
  20. 20.
    Cummings J, Boyd G, Ethell BT, et al. Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation. Biochem Pharmacol 2002; 63(4): 607–13PubMedCrossRefGoogle Scholar
  21. 21.
    Bock KW. Vertebrate UDP-glucuronosyltransferases: functional and evolutionary aspects. Biochem Pharmacol 2003; 66(5): 691–6PubMedCrossRefGoogle Scholar
  22. 22.
    Dehal SS, Kupfer D. Evidence that the catechol 3,4-dihydroxytamoxifen is a proximate intermediate to the reactive species binding covalently to proteins. Cancer Res 1996; 56: 1283–90PubMedGoogle Scholar
  23. 23.
    Dehal SS, Kupfer D. Cytochrome P-450 3A and 2D6 catalyze Ortho hydroxylation of 4-hydroxytamoxifen and 3-hydroxytamoxifen (droloxifene) yielding tamoxifen catechol: involvement of catechols in covalent binding to hepatic proteins. Drug Metab Dispos 1999; 27: 681–8PubMedGoogle Scholar
  24. 24.
    Pelkonen O, Raunio H. Metabolic activation of toxins: tissuespecific expression and metabolism in target organs. Environ Health Perspect 1997; 105: 767–74PubMedGoogle Scholar
  25. 25.
    Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 1997; 37: 269–96PubMedCrossRefGoogle Scholar
  26. 26.
    Aklillu E, Persson I, Bertilsson L, et al. Frequent distribution of rapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 1996; 278: 441–6PubMedGoogle Scholar
  27. 27.
    Tribut O, Lessard Y, Reymann JM, et al. Pharmacogenomics. Med Sci Monit 2002; 8: 152–63Google Scholar
  28. 28.
    Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999; 39: 1–17PubMedCrossRefGoogle Scholar
  29. 29.
    Lamba JK, Lin YS, Schuetz EG, et al. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002; 54: 1271–94PubMedCrossRefGoogle Scholar
  30. 30.
    Lin YS, Dowling AL, Quigley SD, et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 2002; 62: 162–72PubMedCrossRefGoogle Scholar
  31. 31.
    Tateishi T, Watanabe M, Moriya H, et al. No ethnic difference between Caucasian and Japanese hepatic samples in the expression frequency of CYP3A5 and CYP3A7 proteins. Biochem Pharmacol 1999; 57: 935–9PubMedCrossRefGoogle Scholar
  32. 32.
    Dai D, Tang J, Rose R, et al. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther 2001; 299: 825–31PubMedGoogle Scholar
  33. 33.
    Hirth J, Watkins PB, Strawderman M, et al. The effect of an individual’s cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 2000; 6: 1255–8PubMedGoogle Scholar
  34. 34.
    Tran JQ, Kovacs SJ, McIntosh TS, et al. Morning spot and 24-hour urinary 6 beta-hydroxycortisol to Cortisol ratios: intraindividual variability and correlation under basal conditions and conditions of CYP 3A4 induction. J Clin Pharmacol 1999; 39: 487–94PubMedGoogle Scholar
  35. 35.
    Yamamoto N, Tamura T, Kamiya Y, et al. Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous Cortisol. J Clin Oncol 2000; 18: 2301–8PubMedGoogle Scholar
  36. 36.
    Goh BC, Lee SC, Wang LZ, et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 2002; 20: 3683–90PubMedCrossRefGoogle Scholar
  37. 37.
    Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001; 52: 349–55PubMedCrossRefGoogle Scholar
  38. 38.
    Dai D, Zeldin DC, Blaisdell JA, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001; 11: 597–607PubMedCrossRefGoogle Scholar
  39. 39.
    Murray GI, Taylor MC, McFadyen MC, et al. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res 1997; 57: 3026–31PubMedGoogle Scholar
  40. 40.
    Rochat B, Morsman JM, Murray GI, et al. Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther 2001; 296: 537–41PubMedGoogle Scholar
  41. 41.
    McFadyen MC, McLeod HL, Jackson FC, et al. Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. Biochem Pharmacol 2001; 62: 207–12PubMedCrossRefGoogle Scholar
  42. 42.
    Chua MS, Kashiyama E, Bradshaw TD, et al. Role of CYP1 A1 in modulation of antitumor properties of the novel agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495) in human breast cancer cells. Cancer Res 2000; 60: 5196–203PubMedGoogle Scholar
  43. 43.
    Dhaini HR, Thomas DG, Giordano TJ, et al. Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma. J Clin Oncol 2003; 21: 2481–5PubMedCrossRefGoogle Scholar
  44. 44.
    Miyoshi Y, Ando A, Takamura Y, et al. Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues. Int J Cancer 2002; 97: 129–32PubMedCrossRefGoogle Scholar
  45. 45.
    Cummings J, Ethell BT, Jardine L, et al. Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives. Cancer Res 2003; 63(23): 8443–50PubMedGoogle Scholar
  46. 46.
    Kan O, Kingsman S, Naylor S. Cytochrome P450-based cancer gene therapy: current status. Expert Opin Biol Ther 2002; 2: 857–68PubMedCrossRefGoogle Scholar
  47. 47.
    Chen L, Waxman DJ. Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer. Curr Pharm Des 2002; 8: 1405–16PubMedCrossRefGoogle Scholar
  48. 48.
    Rochat B. Evaluation of recombinant cytochrome P450 activity in metabolic pathways [letter]. Drug Metab Dispos 2003; 31: 1–2CrossRefGoogle Scholar
  49. 49.
    Venkatakrishnan K, von Moltke LL, Court MH, et al. Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab Dispos 2000; 28: 1493–504PubMedGoogle Scholar
  50. 50.
    Chang TK, Weber GF, Crespi CL, et al. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 1993; 53: 5629–37PubMedGoogle Scholar
  51. 51.
    Ren S, Yang JS, Kalhorn TF, et al. Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes. Cancer Res 1997; 57: 4229–35PubMedGoogle Scholar
  52. 52.
    Bohnenstengel F, Hofmann U, Eichelbaum M, et al. Characterization of the cytochrome P450 involved in side-chain oxidation of cyclophosphamide in humans. Eur J Clin Pharmacol 1996; 51: 297–301PubMedCrossRefGoogle Scholar
  53. 53.
    Chen L, Waxman DJ, Chen D, et al. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. Cancer Res 1996; 56: 1331–40PubMedGoogle Scholar
  54. 54.
    White IN, De Matteis F, Gibbs AH, et al. Species differences in the covalent binding of [14C]tamoxifen to liver microsomes and the forms of cytochrome P450 involved. Biochem Pharmacol 1995; 49: 1035–42PubMedCrossRefGoogle Scholar
  55. 55.
    Innocenti F, Iyer L, Ratain MJ. Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan. Drug Metab Dispos 2001; 29: 596–600PubMedGoogle Scholar
  56. 56.
    Meisel C, Roots I, Cascorbi I, et al. How to manage individualized drug therapy: application of pharmacogenetic knowledge of drug metabolism and transport. Clin Chem Lab Med 2000; 38: 869–76PubMedCrossRefGoogle Scholar
  57. 57.
    Brockmoller J, Kirchheiner J, Meisel C, et al. Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment. Pharmacogenomics 2000; 1: 125–51PubMedCrossRefGoogle Scholar
  58. 58.
    Ma MK, Woo MH, McLeod HL. Genetic basis of drug metabolism. Am J Health Syst Pharm 2002; 59: 2061–9PubMedGoogle Scholar
  59. 59.
    Relling MV, Dervieux T. Pharmacogenetics and cancer therapy. Nat Rev Cancer 2001; 1: 99–108PubMedCrossRefGoogle Scholar
  60. 60.
    Bachmann KA. Genotyping and phenotyping the cytochrome P-450 enzymes. Am J Ther 2002; 9: 309–16PubMedCrossRefGoogle Scholar
  61. 61.
    Kivisto KT, Kroemer HK. Use of probe drugs as predictors of drug metabolism in humans. J Clin Pharmacol 1997; 37(1 Suppl.): 40–8SGoogle Scholar
  62. 62.
    Zhu B, Ou-Yang DS, Chen XP, et al. Assessment of cytochrome P450 activity by a five-drug cocktail approach. Clin Pharmacol Ther 2001; 70: 455–61PubMedCrossRefGoogle Scholar
  63. 63.
    Conus P, Bondolfi G, Eap CB, et al. Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient. Pharmacopsychiatry 1996; 29: 108–10PubMedCrossRefGoogle Scholar
  64. 64.
    Baumann P, Broly F, Kosel M, et al. Ultrarapid metabolism of clomipramine in a therapy-resistant depressive patient, as confirmed by CYP2D6 genotyping [letter]. Pharmacopsychiatry 1998; 31: 72PubMedCrossRefGoogle Scholar
  65. 65.
    Krynetski EY, Evans WE. Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm. Pharm Res 1999; 16: 342–9PubMedCrossRefGoogle Scholar
  66. 66.
    Huitema AD, Mathot RA, Tibben MM, et al. Validation of a therapeutic drug monitoring strategy for thiotepa in a high-dose chemotherapy regimen. Ther Drug Monit 2001; 23: 650–7PubMedCrossRefGoogle Scholar
  67. 67.
    Huitema AD, Mathot RA, Tibben MM, et al. Validation of a therapeutic drug monitoring strategy for thiotepa in a high-dose chemotherapy regimen. Ther Drug Monit 2001; 23: 650–7PubMedCrossRefGoogle Scholar
  68. 68.
    Rivory LP, Slaviero KA, Hoskins JM, et al. The erythromycin breath test for the prediction of drug clearance. Clin Pharmacokinet 2001; 40: 151–8PubMedCrossRefGoogle Scholar
  69. 69.
    Sreerama L, Sladek NE. Primary breast tumor levels of suspected molecular determinants of cellular sensitivity to cyclophosphamide, ifosfamide, and certain other anticancer agents as predictors of paired metastatic tumor levels of these determinants: rational individualization of cancer chemotherapeutic regimens. Cancer Chemother Pharmacol 2001; 47: 255–62PubMedCrossRefGoogle Scholar
  70. 70.
    Veenstra DL, Higashi MK, Phillips KA. Assessing the costeffectiveness of pharmacogenomics. AAPS PharmSci 2000; 2: E29PubMedCrossRefGoogle Scholar
  71. 71.
    Jordan VC, Dix CJ, Rowsby L, et al. Studies on the mechanism of action of the nonsteroidal antioestrogen tamoxifen (I.C.I. 46,474) in the rat. Mol Cell Endocrinol 1977; 7: 177–92PubMedCrossRefGoogle Scholar
  72. 72.
    Stearns V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003; 95(23): 1758–64PubMedCrossRefGoogle Scholar
  73. 73.
    Johnson MD, Zuo H, Lee KH, et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 2004; 85(2): 151–9PubMedCrossRefGoogle Scholar
  74. 74.
    MacCallum J, Cummings J, Dixon JM, et al. Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours. Br J Cancer 2000; 82: 1629–35PubMedCrossRefGoogle Scholar
  75. 75.
    Poon GK, Walter B, Lonning PE, et al. Identification of tamoxifen metabolites in human Hep G2 cell line, human liver homogenate, and patients on long-term therapy for breast cancer. Drug Metab Dispos 1995; 23: 377–82PubMedGoogle Scholar
  76. 76.
    Phillips DH. Understanding the genotoxicity of tamoxifen? Carcinogenesis 2001; 22: 839–49PubMedCrossRefGoogle Scholar
  77. 77.
    Crewe HK, Ellis SW, Lennard MS, et al. Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol 1997; 53: 171–8PubMedCrossRefGoogle Scholar
  78. 78.
    Dehal SS, Kupfer D. CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res 1997; 57: 3402–6PubMedGoogle Scholar
  79. 79.
    Coller JK, Krebsfaenger N, Klein K, et al. The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. Br J Clin Pharmacol 2002; 54: 157–67PubMedCrossRefGoogle Scholar
  80. 80.
    Boocock DJ, Maggs JL, Brown K, et al. Major inter-species differences in the rates of O-sulphonation and O-glucuronylation of alpha-hydroxytamoxifen in vitro: a metabolic disparity protecting human liver from the formation of tamoxifen-DNA adducts. Carcinogenesis 2000; 21: 1851–8PubMedCrossRefGoogle Scholar
  81. 81.
    Mani C, Kupfer D. Cytochrome P-450-mediated activation and irreversible binding of the antiestrogen tamoxifen to proteins in rat and human liver: possible involvement of flavin-containing monooxygenases in tamoxifen activation. Cancer Res 1991; 51: 6052–8PubMedGoogle Scholar
  82. 82.
    Mani C, Pearce R, Parkinson A, et al. Involvement of cytochrome P4503A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes. Carcinogenesis 1994; 15: 2715–20PubMedCrossRefGoogle Scholar
  83. 83.
    Divi RL, Dragan YP, Pitot HC, et al. Immunohistochemical localization and semi-quantitation of hepatic tamoxifen-DNA adducts in rats exposed orally to tamoxifen. Carcinogenesis 2001; 22: 1693–9PubMedCrossRefGoogle Scholar
  84. 84.
    Boocock DJ, Brown K, Gibbs AH, et al. Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. Carcinogenesis 2002; 23: 1897–901PubMedCrossRefGoogle Scholar
  85. 85.
    Moorthy B, Sriram P, Randerath E, et al. Effects of cytochrome P450 inducers on tamoxifen genotoxicity in female mice in vivo. Biochem Pharmacol 1997; 53: 663–9PubMedCrossRefGoogle Scholar
  86. 86.
    Comoglio A, Gibbs AH, White IN, et al. Effect of tamoxifen feeding on metabolic activation of tamoxifen by the liver of the rhesus monkey: does liver accumulation of inhibitory metabolites protect from tamoxifen-dependent genotoxicity and cancer? Carcinogenesis 1996; 8: 1687–93CrossRefGoogle Scholar
  87. 87.
    Carter SJ, Li XF, Mackey JR, et al. Biomonitoring of urinary tamoxifen and its metabolites from breast cancer patients using nonaqueous capillary electrophoresis with electrospray mass spectrometry. Electrophoresis 2001; 22: 2730–6PubMedCrossRefGoogle Scholar
  88. 88.
    Clarke R, Skaar TC, Bouker KB, et al. Molecular and pharmacological aspects of antiestrogen resistance. J Steroid Biochem Mol Biol 2001; 76: 71–84PubMedCrossRefGoogle Scholar
  89. 89.
    Osborne CK, Jarman M, McCague R, et al. The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother Pharmacol 1994; 34: 89–95PubMedCrossRefGoogle Scholar
  90. 90.
    Crewe HK, Notley LM, Wunsch RM, et al. Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4t′-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos 2002; 30: 869–74PubMedCrossRefGoogle Scholar
  91. 91.
    Williams ML, Lennard MS, Martin IJ, et al. Interindividual variation in the isomerization of 4-hydroxytamoxifen by human liver microsomes: involvement of cytochromes P450. Carcinogenesis 1994; 15: 2733–8PubMedCrossRefGoogle Scholar
  92. 92.
    Sharma M, Shubert DE, Sharma M, et al. Biotransformation of tamoxifen in a human endometrial expiant culture model. Chem Biol Interact 2003; 146(3): 237–49PubMedCrossRefGoogle Scholar
  93. 93.
    McFadyen MC, Breeman S, Payne S, et al. Immunohistochemical localization of cytochrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for CYP1B1. J Histochem Cytochem 1999; 47: 1457–64PubMedCrossRefGoogle Scholar
  94. 94.
    Parekh H, Simpkins H. The transport and binding of taxol. Gen Pharmacol 1997; 29: 167–72PubMedCrossRefGoogle Scholar
  95. 95.
    O’Leary J, Volm M, Wasserheit C, et al. Taxanes in adjuvant and neoadjuvant therapies for breast cancer. Oncology 1998; 12: 23–7PubMedGoogle Scholar
  96. 96.
    Kumar G, Ray S, Walle T, et al. Comparative in vitro cytotoxic effects of taxol and its major human metabolite 6 alphahydroxytaxol. Cancer Chemother Pharmacol 1995; 36: 129–35PubMedCrossRefGoogle Scholar
  97. 97.
    Harris JW, Katki A, Anderson LW, et al. Isolation, structural determination, and biological activity of 6 alpha-hydroxytaxol, the principal human metabolite of taxol. J Med Chem 1994; 37: 706–9PubMedCrossRefGoogle Scholar
  98. 98.
    Sonnichsen DS, Liu Q, Schuetz EG, et al. Variability in human cytochrome P450 paclitaxel metabolism. J Pharmacol Exp Ther 1995; 275: 566–75PubMedGoogle Scholar
  99. 99.
    Monsarrat B, Chatelut E, Royer I, et al. Modification of paclitaxel metabolism in a cancer patient by induction of cytochrome P450 3A4. Drug Metab Dispos 1998; 26: 229–33PubMedGoogle Scholar
  100. 100.
    Cresteil T, Monsarrat B, Alvinerie P, et al. Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res 1994; 54: 386–92PubMedGoogle Scholar
  101. 101.
    Rahman A, Korzekwa KR, Grogan J, et al. Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 1994; 54: 5543–6PubMedGoogle Scholar
  102. 102.
    Mechetner E, Kyshtoobayeva A, Zonis S, et al. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res 1998; 4: 389–98PubMedGoogle Scholar
  103. 103.
    Sarris AH, Younes A, McLaughlin P, et al. Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin’s lymphoma. J Clin Oncol 1996; 14: 233–9PubMedGoogle Scholar
  104. 104.
    Miller TP, Chase EM, Dorr R, et al. A phase I/II trial of paclitaxel for non-Hodgkin’s lymphoma followed by paclitaxel plus quinine in drug-resistant disease. Anticancer Drugs 1998; 9: 135–40PubMedCrossRefGoogle Scholar
  105. 105.
    Brinkmann U. Functional polymorphisms of the human multidrug resistance (MDR1) gene: correlation with P glycoprotein expression and activity in vivo. Novartis Found Symp 2002; 243: 207–10PubMedCrossRefGoogle Scholar
  106. 106.
    Yu D, Liu B, Jing T, et al. Overexpression of both p185c-erbB2 and p170mdr-l renders breast cancer cells highly resistant to taxol. Oncogene 1998; 16: 2087–94PubMedCrossRefGoogle Scholar
  107. 107.
    Huang Y, Ibrado AM, Reed JC, et al. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia 1997; 11: 253–7PubMedCrossRefGoogle Scholar
  108. 108.
    Kavallaris M, Kuo DYS, Burkhart CA, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 1997; 100: 1282–93PubMedCrossRefGoogle Scholar
  109. 109.
    Giannakakou P, Sackett DL, Kang YK, et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997; 272: 17118–25PubMedCrossRefGoogle Scholar
  110. 110.
    Monzo M, Rosell R, Sanchez JJ, et al. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol 1999; 17: 1786–93PubMedGoogle Scholar
  111. 111.
    Ohta S, Nishio K, Kubota N, et al. Characterization of a taxolresistant human small-cell lung cancer cell line. Jpn J Cancer Res 1994; 85: 290–7PubMedCrossRefGoogle Scholar
  112. 112.
    Parekh H, Simpkins H. Species-specific differences in taxol transport and cytotoxicity against human and rodent tumor cells: evidence for an alternate transport system. Biochem Pharmacol 1996; 51: 301–11PubMedCrossRefGoogle Scholar
  113. 113.
    Parekh H, Wiesen K, Simpkins H. Acquisition of taxol resistance via P-glycoprotein- and non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma cells. Biochem Pharmacol 1997; 53: 461–70PubMedCrossRefGoogle Scholar
  114. 114.
    Kern DH. Heterogeneity of drug resistance in human breast and ovarian cancers. Cancer J Sci Am 1998; 4: 41–5PubMedGoogle Scholar
  115. 115.
    Lee DK, Kim YH, Kim JS, et al. Induction and characterization of taxol-resistance phenotypes with a transiently expressed artificial transcriptional activator library. Nucleic Acids Res 2004; 32(14): E1–16CrossRefGoogle Scholar
  116. 116.
    Savage DG, Antman KH. Imatinib mesylate: a new oral targeted therapy. N Engl J Med 2002; 346: 683–93PubMedCrossRefGoogle Scholar
  117. 117.
    O’Dwyer ME, Druker BJ. STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia. Lancet Oncol 2000; 1: 207–11PubMedCrossRefGoogle Scholar
  118. 118.
    Buchdunger E, Matter A, Druker BJ. Bcr-Abl inhibition as a modality of CML therapeutics. Biochim Biophys Acta 2001; 1551: M11–8PubMedGoogle Scholar
  119. 119.
    Verweij J, Judson I, van Oosterom A. STI571: a magic bullet? Eur J Cancer 2001; 37: 1816–9PubMedCrossRefGoogle Scholar
  120. 120.
    Fabbro D, Ruetz S, Buchdunger E, et al. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol Ther 2002; 93: 79–98PubMedCrossRefGoogle Scholar
  121. 121.
    Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002; 347: 481–7PubMedCrossRefGoogle Scholar
  122. 122.
    Cohen MH, Williams G, Johnson JR, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 2002; 8: 935–42PubMedGoogle Scholar
  123. 123.
    Kantarjian HM, Cortes J, O’Brien S, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast crisis. Blood 2002; 99: 3547–53PubMedCrossRefGoogle Scholar
  124. 124.
    Krystal GW. Mechanisms of resistance to imatinib (STI571) and prospects for combination with conventional chemotherapeutic agents. Drug Resist Updat 2001; 4: 16–21PubMedCrossRefGoogle Scholar
  125. 125.
    McCormick F. New-age drug meets resistance. Nature 2001; 412: 281–2PubMedCrossRefGoogle Scholar
  126. 126.
    Shah N, Nicoll J, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117–25PubMedCrossRefGoogle Scholar
  127. 127.
    Roumiantsev S, Shah NP, Gorre ME, et al. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci U S A 2002; 99: 10700–5PubMedCrossRefGoogle Scholar
  128. 128.
    Hofmann WK, Jones LC, Lemp NA, et al. Ph (+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 2002; 99: 1860–2PubMedCrossRefGoogle Scholar
  129. 129.
    Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876–80PubMedCrossRefGoogle Scholar
  130. 130.
    Von Bubnoff N, Schneller F, Peschel C, et al. BCR-ABL gene mutations in relation to clinical resistance of Philadelphiachromosome-positive leukaemia to STI571: a prospective study. Lancet 2002; 359: 487–91CrossRefGoogle Scholar
  131. 131.
    Branford S, Rudzki Z, Walsh S, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002; 99: 3472–5PubMedCrossRefGoogle Scholar
  132. 132.
    Le Coutre P, Tassi E, Varella-Garcia M, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000; 95: 1758–66PubMedGoogle Scholar
  133. 133.
    Keeshan K, Mills KI, Cotter TG, et al. Elevated Bcr-Abl expression levels are sufficient for a haematopoietic cell line to acquire a drug-resistant phenotype. Leukemia 2001; 15: 1823–33PubMedCrossRefGoogle Scholar
  134. 134.
    Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000; 96: 1070–9PubMedGoogle Scholar
  135. 135.
    Hegedus T, Orfi L, Seprodi A, et al. Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim Biophys Acta 2002; 1587: 318–25PubMedCrossRefGoogle Scholar
  136. 136.
    Illmer T, Schaich M, Platzbecker U, et al. P-glycoproteinmediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 2004; 18: 401–8PubMedCrossRefGoogle Scholar
  137. 137.
    Ozvegy-Laczka C, Hegedus T, Varady G, et al. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 2004; 65(6): 1485–95PubMedCrossRefGoogle Scholar
  138. 138.
    Le Coutre P, Kreuzer KA, Il-Kang NA. Determination of alpha-1 acid glycoprotein in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571. Blood Cells Mol Dis 2002; 28: 75–85PubMedCrossRefGoogle Scholar
  139. 139.
    Gambacorti-Passerini C, Barni R, Le Coutre P, et al. Role of alphal acid glycoprotein in the in vivo resistance of human BCR-ABL (+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 2000; 92: 1641–50PubMedCrossRefGoogle Scholar
  140. 140.
    Larghero J, Leguay T, Mourah S, et al. Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo. Biochem Pharmacol 2003; 66(10): 1907–13PubMedCrossRefGoogle Scholar
  141. 141.
    Gambacorti-Passerini CB, Rossi F, Verga M, et al. Differences between in vivo and in vitro sensitivity to imatinib of Bcr/Abl+ cells obtained from leukemic patients. Blood Cells Mol Dis 2002; 28: 361–72PubMedCrossRefGoogle Scholar
  142. 142.
    Gambacorti-Passerini C, Zucchetti M, Russo D, et al. Alphal acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 2003; 9(2): 625–32PubMedGoogle Scholar
  143. 143.
    Tipping AJ, Deininger MW, Goldman JM, et al. Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate. Exp Hematol 2003; 31: 1073–80PubMedGoogle Scholar
  144. 144.
    McLean LA, Gatmann I, Capdeville R, et al. Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib. Clin Cancer Res 2004; 10: 155–65PubMedCrossRefGoogle Scholar
  145. 145.
    Kikuta Y, Yamashita Y, Kashiwagi S, et al. Expression and induction of CYP4F subfamily in human leukocytes and HL60 cells. Biochim Biophys Acta 2004; 1683(1–3): 7–15PubMedGoogle Scholar
  146. 146.
    CDER new and generic drug approvals: 1998–2004 [online]. Available from URL: http://www.fda.gov/cder/approval/index.htm [Accessed 2005 Mar 10]
  147. 147.
    Lin YS, Lockwood GF, Graham MA, et al. In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics 2001; 11: 781–91PubMedCrossRefGoogle Scholar
  148. 148.
    Baron JM, Zwadlo-Klarwasser G, Jugert F, et al. Cytochrome P450 1B1: a major P450 isoenzyme in human blood monocytes and macrophage subsets. Biochem Pharmacol 1998; 56: 1105–10PubMedCrossRefGoogle Scholar
  149. 149.
    Spencer DL, Masten SA, Lanier KM, et al. Quantitative analysis of constitutive and 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced cytochrome P450 1B1 expression in human lymphocytes. Cancer Epidemiol Biomarkers Prev 1999; 8: 139–46PubMedGoogle Scholar
  150. 150.
    Finnstrom N, Ask B, Dahl ML, et al. Intra-individual variation and sex differences in gene expression of cytochromes P450 in circulating leukocytes. Pharmacogenomics J 2002; 2: 111–6PubMedCrossRefGoogle Scholar
  151. 151.
    Bernauer U, Garritsen H, Heinrich-Hirsch B, et al. Immunochemical analysis of cytochrome P450 variability in human leukapheresed samples and its consequences for the risk assessment process. Regul Toxicol Pharmacol 2003; 37(2): 318–27PubMedCrossRefGoogle Scholar
  152. 152.
    Al-Ali HK, Heinrich MC, Lange T, et al. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Hematol J 2004; 5(1): 55–60PubMedCrossRefGoogle Scholar
  153. 153.
    Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003; 102(1): 276–83PubMedCrossRefGoogle Scholar
  154. 154.
    Barthe C, Cony-Makhoul P, Melo JV, et al. Roots of clinical resistance to STI-571 cancer therapy. Science 2001; 293: 2163PubMedCrossRefGoogle Scholar
  155. 155.
    Hochhaus A, Kreil S, Corbin A, et al. Roots of clinical resistance to STI-571 cancer therapy. Science 2001; 293: 2163PubMedCrossRefGoogle Scholar
  156. 156.
    Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002; 100: 1014–8PubMedCrossRefGoogle Scholar
  157. 157.
    Shah NP, Sawyers CL. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene 2003; 22(47): 7389–95PubMedCrossRefGoogle Scholar
  158. 158.
    McLeod HL. Individualized cancer therapy: molecular approaches to the prediction of tumor response. Expert Rev Anticancer Ther 2002; 2: 113–9PubMedCrossRefGoogle Scholar
  159. 159.
    Peters GJ, Backus HH, Freemantle S, et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 2002 Jul 18; 1587: 194–205PubMedCrossRefGoogle Scholar
  160. 160.
    McLeod HL, Siva C. The thiopurine S-methyltransferase gene locus: implications for clinical pharmacogenomics. Pharmacogenomics 2002; 3: 89–98PubMedCrossRefGoogle Scholar
  161. 161.
    Salonga D, Danenberg KD, Johnson M, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine Phosphorylase. Clin Cancer Res 2000; 6: 1322–7PubMedGoogle Scholar
  162. 162.
    Scappini B, Gatto S, Onida F, et al. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein. Cancer 2004; 100(7): 1459–71PubMedCrossRefGoogle Scholar
  163. 163.
    Nimmanapalli R, O’Bryan E, Huang M, et al. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. Cancer Res 2002; 62(20): 5761–9PubMedGoogle Scholar
  164. 164.
    Donate NJ, Wu JY, Stapley J, et al. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 2004; 64(2): 672–67CrossRefGoogle Scholar
  165. 165.
    Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190–6PubMedCrossRefGoogle Scholar
  166. 166.
    Hofmann WK, de Vos S, Elashoff D, et al. Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study. Lancet 2002; 359: 481–6PubMedCrossRefGoogle Scholar
  167. 167.
    Hoover RR, Mahon FX, Melo JV, et al. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood 2002; 100: 1068–71PubMedCrossRefGoogle Scholar
  168. 168.
    Luzzatto L, Melo JV. Acquired resistance to imatinib mesylate: selection for pre-existing mutant cells [letter]. Blood 2002; 100: 1105PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  1. 1.Centre Hospitalier Universitaire VaudoisLausanneSwitzerland

Personalised recommendations